Myriad Genetics is genetic testing and precision medicine company. Co. provides insights that help people take control of their health and enable healthcare providers to detect, treat, and prevent disease. Co. discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, or guide treatment decisions across medical personnel. Co.'s molecular diagnostic tests are designed to analyze genes and their expression levels to assess an individual's risk for developing disease, determine a patient's likelihood of responding to a particular drug, or assess a patient's risk of disease progression. We show 58 historical shares outstanding datapoints in our MYGN shares outstanding history coverage, used to compute MYGN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MYGN market cap history over the course of time is important for investors
interested in comparing MYGN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MYGN versus a peer is one thing; comparing
MYGN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MYGN can fluctuate over the course of history.
With this page we aim to empower investors researching MYGN by allowing them to research the MYGN market cap history. |
Free MYGN Email Alerts:
Video: The Importance of Market Cap
